Minerva Neurosciences, Inc.:
Ph 3 trial w/roluperidone targeting negative symptoms assoc w/ schizophrenia; dual MOA (5-HT2A & Sigma2 antagonist); top-line data 1H19. 3 Ph 2b trials ongoing w/ seltorexant, including two in MDD and one in insomnia disorder. Trials planned for completion in 2019. Co-devt & license agreement w/Janssen in place for seltorexant.
1601 Trapelo Road, Suite 284
Waltham, MA 02451
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by